NanoString Technologies (NASDAQ: NSTG), a provider of life science tools for discovery and translational research, announced on Wednesday that it has introduced the GeoMx IO Proteome Atlas (IPA), a spatial proteomics assay for the GeoMx Digital Spatial Profiler (DSP). This assay allows the spatial profiling of over 500 immuno-oncology (IO) relevant targets in FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections.

Leveraging IHC-compatible antibodies from abcam's IO portfolio, the GeoMx IPA offers five times more content than competing panels, making it a powerful tool for biomarker discovery, drug target investigation, therapeutic response assessment, patient stratification and drug mechanism elucidation.

Researchers can run the GeoMx IPA independently or alongside GeoMx WTA (Whole Transcriptome Analysis) and seamlessly integrate the data from both assays. This launch marks the continuation of NanoString's collaboration with abcam in providing validated antibodies for spatial analysis, following their joint effort in developing a 64-plex panel for NanoString's CosMx Spatial Molecular Imager.

While primarily designed for IO research, GeoMx IPA has broad applications in fields such as infectious disease, organ transplant, autoimmunity, metabolism and epigenetics. Researchers can now access a wealth of spatial proteomic data from FFPE tissue samples, simplifying biomarker discovery and drug target investigations.

The GeoMx IPA assay is available for pre-order, with shipments expected to commence in Q4 2023.